摘要
目的分析术前吉西他滨联合顺铂(GP)新辅助化疗对局部晚期非小细胞肺癌(NSCLC)手术患者预后的影响因素。方法回顾性分析2014年1月—2015年5月收治的121例局部晚期NSCLC患者的临床资料,所有患者均采用手术治疗,其中术前给予GP新辅助化疗患者68例。根据术后是否死亡将患者分存活组40例和死亡组81例,采用非条件单因素和多因素Logistic回归模型分析影响NSCLC手术患者预后死亡的危险因素。结果经单因素分析结果显示,吸烟指数、治疗方式、手术方式和手术并发症是影响NSCLC手术患者预后死亡的相关因素(P<0.05);经非条件多因素Logistic回归模型分析结果显示,吸烟指数>400支/年、直接手术、全肺切除是影响NSCLC手术患者预后死亡的独立危险因素(P<0.05)。结论术前GP新辅助化疗联合手术治疗可以提高局部晚期NSCLC患者的预后生存率,术前未进行GP新辅助化疗是影响患者预后死亡的独立危险因素。
Objective To analyze influencing factors of preoperative neoadjuvant chemotherapy with Gemcitabine and Cisplatin (GP) on prognosis of patients with locally advanced non-small cell lung cancer (NSCLC) undergoing surgery. Methods Clinical data of 121 patients with locally advanced NSCLC admitted during January 2014 and May 2015 was retrospectively analyzed. All patients underwent surgical treatments, which included 68 patients with preoperative GP neoadjuvant chemotherapy. The patients were divided into survival group ( n =40) and death group ( n =81) according to whether or not having death. Risk factors affecting prognosis and mortality of NSCLC patients were analyzed by unconditional univariate and multivariate logistic regression model. Results Univariate analysis showed that smoking index, therapeutic methods, operative methods and complications were related factors affecting prognosis and mortality of NSCLC patients ( P <0.05);unconditional multivariate logistic regression model analysis showed that smoking index more than 400 branches per year, direct operation and total pneumonectomy were independent risk factors affecting prognosis and mortality of NSCLC patients ( P <0.05). Conclusion Preoperative GP neoadjuvant chemotherapy combined with surgical treatment may improve prognostic survival rate of patients with locally advanced NSCLC. Preoperative non-GP neoadjuvant chemotherapy is an independent risk factor affecting prognosis and mortality of patients.
作者
刘哲
程亮亮
于显凤
LIU Zhe;CHENG Liang-liang;YU Xian-feng(The Third Department of Oncology,Central Hospital of Liaoyang,Liaoyang,Liaoning 111000,China)
出处
《解放军医药杂志》
CAS
2019年第6期25-28,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
辽宁省自然科学基金(20170541040)
关键词
化学疗法
辅助
癌
非小细胞肺
预后
危险因素
Chemotherapy, adjuvant
Carcinoma, non-small-cell lung
Prognosis
Risk factors
